Dr. Geyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6445 Main St
Floor 24
Houston, TX 77030Phone+1 713-441-9948Fax+1 713-441-8791
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1986- Baylor College of MedicineFellowship, Hematology, 1984 - 1984
- Baylor College of MedicineResidency, Internal Medicine, 1980 - 1983
Texas Tech University Health Sciences Center School of MedicineClass of 1980
Certifications & Licensure
PA State Medical License 2002 - 2024
TX State Medical License 1980 - 2024
VA State Medical License 2013 - 2024
FL State Medical License 2013 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Start of enrollment: 2014 Apr 22
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Start of enrollment: 2019 Apr 05
Publications & Presentations
PubMed
- 2 citationsPatient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gMutations and High-Risk Human Epidermal Growth Factor ...Patricia A Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller
Journal of Clinical Oncology. 2024-04-10 - 8 citationsBiomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast...Carsten Denkert, Chiara Lambertini, Peter A Fasching, Katherine L Pogue-Geile, Max S Mano
Clinical Cancer Research. 2023-04-14 - 15 citationsMatched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter Ansell, Mark A. Watson
NPJ Breast Cancer. 2021-11-11
Journal Articles
- Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCharles E Geyer, William M Sikov, JAMA Oncology
Lectures
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with ...2019 ASCO Annual Meeting - 6/1/2019
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study FindsJune 3rd, 2021
Not All Node-Positive Breast Cancers Benefit from ChemotherapyAugust 13th, 2019
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast CancerApril 1st, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
